

AMENDMENT TO THE CLAIMS

Claims 1-20 (cancelled)

EJ
^{Currently}
Claim 21. (Previously Amended) An isolated polypeptide fragment of *Clostridium sordellii* lethal Toxin (LT) with glucosyltransferase activity, consisting essentially of approximately the first 1020 N-terminal amino acids of the amino acid sequence of *Clostridium sordellii* lethal Toxin (LT) according to SEQ ID NO: 6.

Claim 22. (Currently Amended) A compound ~~comprising~~ consisting of a polypeptide fragment of *Clostridium sordellii* lethal Toxin (LT) consisting essentially of approximately the first 1020 amino acids of the amino acid sequence of *Clostridium sordellii* lethal Toxin (LT) according to SEQ ID NO: 1 or a portion thereof, the compound having (i) a glucosyltransferase activity domain, and (ii) a target cell specific binding domain which permits the compound to bind to a target cell.

Claim 23. (Currently Amended) A compound ~~comprising~~ consisting of a polypeptide fragment of *Clostridium sordellii* lethal Toxin (LT) consisting essentially of approximately the first 1020 amino acids of the amino acid sequence of *Clostridium sordellii* lethal Toxin (LT) as defined by SEQ ID NO: 1 or a portion thereof, the compound having (i) a glucosyltransferase activity domain, (ii) a target cell specific binding domain, which domain causes the compound to bind to a target cell, and (iii) a translocation domain causes the compound to bind to a target cell, and (iv) a translocation domain for translocating a catalytic domain of *Clostridium sordellii* lethal Toxin (LT) from the exterior of a cell into the interior of said cell.

Claim 24. (Previously Added) A compound according to claim 23, wherein the translocation domain consists essentially of approximately the N-terminal amino acids 1021-1700 of the amino acid sequence of *Clostridium sordellii* lethal Toxin (LT).

Claim 25. (Previously Added) A compound according to one of claims 22 to 24, wherein the target cell specific binding domain is an antibody or an antigen binding fragment thereof.

BS
Conclude

Claim 26. (Currently Amended) A composition comprising consisting of a compound according to one of claims 22 to 24 and a pharmaceutically acceptable adjuvant or carrier.

Claim 27. (Currently Amended) A composition comprising consisting of a compound according to claim 25 and a pharmaceutically acceptable adjuvant or carrier.

Claim 28. (Previously Added) A method of manufacturing a composition, said method comprising the steps of bringing together a compound according to one of claims 22 to 24 and a pharmaceutically acceptable adjuvant or carrier.

Claim 29. (Previously Added) A method of manufacturing a composition, said method comprising the steps of bringing together a compound according to claim 25 and a pharmaceutically acceptable adjuvant or carrier.